IceCure Medical Reports 26% Revenue Growth Driven by U.S. ProSense Sales
IceCure Medical (ICCM) reported a 26% increase in total revenue to $2.6 million for the first nine months of 2026, fueled primarily by an 83% surge in U.S. sales for its ProSense tumor destruction system. To support this growth, the company expanded its domestic commercial footprint from 11 states to 21 states, deploying dedicated clinical and sales professionals in key markets like California and Florida. Despite strong top-line momentum and projections for double-digit revenue growth next year, the company faces financial and operational headwinds. Net losses expanded to $12.9 million due to heavy investments in commercialization and clinical studies. Additionally, CEO Eyal Shamir noted that slow contract negotiations at partner sites may delay the target of enrolling 400 patients in the ChoICE clinical study within the planned three-year window.

Topics: Clinical Trials Operating Loss Revenue Growth U.S. Market Expansion